Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG)(Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG))

概要

基本信息

药物类型

病毒样颗粒疫苗、治疗性疫苗

别名

Anti-nicotine immunotherapy、Anti-nicotine virus-like particle vaccine、Immunodrug nicotine addiction vaccine

+ [7]

靶点

nAChRs

作用机制

Nicotinic receptors拮抗剂(烟碱受体拮抗剂)

治疗领域

其他疾病

在研适应症-

非在研适应症

尼古丁依赖尼古丁成瘾烟草依赖

原研机构

Cytos Biotechnology AG

在研机构-

非在研机构

Cytos Biotechnology AG

Wake Forest UniversityDuke University Medical Center

+ [1]

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的临床试验

NCT01280968 / Completed临床2期IIT

Improving the Efficacy of Anti-Nicotine Immunotherapy

The purpose of this study is to find out how vaccine-induced antibodies change the way the body processes nicotine from cigarettes. These antibodies absorb nicotine and can reduce nicotine levels in the brain. In this way, the vaccination may help to quit smoking. The central hypothesis is that anti-nicotine antibodies change kinetics of brain nicotine accumulation and distribution of nicotine between the brain and other body tissues. This vaccine is investigational which means that it is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA) to help people quit smoking.

开始日期2010-12-01

申办/合作机构

Duke University

[+2]

NCT00736047 / Completed临床2期

A Double Blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.

开始日期2008-08-01

申办/合作机构

Novartis AG

EUCTR2007-006741-40-DE / Not yet recruitingN/A

A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers who are motivated to quit smoking

开始日期2008-07-14

申办/合作机构

Novartis Pharma Services AG

100 项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的临床结果

登录后查看更多信息

100 项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的转化医学

登录后查看更多信息

100 项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的专利（医药）

登录后查看更多信息

47

项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的文献（医药）

2024-01-01·Methods in molecular biology (Clifton, N.J.)

Melt Processing Virus-Like Particle-Based Vaccine Candidates into Biodegradable Polymer Implants.

Article

作者: Wirth, David M ; Ortega-Rivera, Oscar A ; Pokorski, Jonathan K ; Steinmetz, Nicole F ; Puente, Armando A

Melt processing is an emerging production method to efficiently encapsulate proteins into polymeric devices for sustained release. In the context of vaccines, melt processing is well-suited to develop vaccine delivery devices that are stable outside the cold chain and can generate protective immunity from a single dose. We have demonstrated the compatibility of bacteriophage Qβ virus-like particles (VLPs) with hot-melt extrusion (HME) and have leveraged this technology to develop a single-dose vaccine candidate for vaccination against human papillomavirus (HPV). Here, we detail the methods for chemically conjugating an HPV peptide epitope from the L2 minor capsid protein to Qβ VLPs to generate HPV-Qβ particles. We outline techniques used to characterize HPV-Qβ particles, and we elaborate on the process to encapsulate HPV-Qβ into biodegradable poly(lactic-co-glycolic acid) (PLGA) implants and discuss methods for the materials characterization of the HPV-Qβ/polymer melts. The methods described could be adapted to other disease targets, i.e., by conjugation of a different peptide epitope, or transferred to other VLP systems suited for conjugation, immune response, or stability during processing. Such VLPs are ideally suited for use in HME, a mature, scalable, continuous, and solvent-free process which can be adapted to mold devices, therefore allowing the processing of the melts into various geometries, such as subcutaneous implants, or self-administrable microneedle patches.

2023-09-20·Bioconjugate Chemistry

TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy

Article

作者: Chung, Young Hun ; Steinmetz, Nicole F ; Jung, Eunkyeong

Toll-like receptors (TLRs) are promising targets in cancer immunotherapy due to their role in activating the immune system; therefore, various small-molecule TLR agonists have been tested in clinical applications. However, the clinical use of TLR agonists is hindered by their non-specific side effects and poor pharmacokinetics. To overcome these limitations, we used plant virus nanoparticles (VNPs) and bacteriophage virus-like particles (VLPs) as drug delivery systems. We conjugated TLR3 or TLR7 agonists to cowpea mosaic virus (CPMV) VNPs, cowpea chlorotic mottle virus (CCMV) VNPs, and bacteriophage Qβ VLPs. The conjugation of TLR7 agonist, 2-methoxyethoxy-8-oxo-9-(4-carboxybenzyl)adenine (1V209), resulted in the potent activation of immune cells and promoted the production of pro-inflammatory cytokine interleukin 6. We found that 1V209 conjugated to CPMV, CCMV, and Qβ reduced tumor growth in vivo and prolonged the survival of mice compared to those treated with free 1V209 or a simple admixture of 1V209 and viral particles. Nucleic acid-based TLR3 agonist, polyinosinic acid with polycytidylic acid (poly(I:C)), was also delivered by CPMV VNPs, resulting in enhanced mice survival. All our data suggest that coupling and co-delivery are required to enhance the anti-tumor efficacy of TLR agonists and simple mixing of the VLPs with the agonists does not confer a survival benefit. The delivery of 1V209 or poly(I:C) conjugated to VNPs/VLPs probably enhances their efficacy due to the multivalent presentation, prolongation of tumor residence time, and targeting of the innate immune cells mediated by the VNP/VLP carrier.

2023-01-18·Bioconjugate Chemistry

Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant

Article

作者: Chung, Young Hun ; Volckaert, Britney A ; Steinmetz, Nicole F

The SARS-CoV-2 pandemic has highlighted the need for vaccines that are effective, but quickly produced. Of note, vaccines with plug-and-play capabilities that co-deliver antigen and adjuvant to the same cell have shown remarkable success. Our approach of utilizing a nitrilotriacetic acid (NTA) histidine (His)-tag chemistry with viral adjuvants incorporates both of these characteristics: plug-and-play and co-delivery. We specifically utilize the cowpea mosaic virus (CPMV) and the virus-like particles from bacteriophage Qβ as adjuvants and bind the model antigen ovalbumin (OVA). Successful binding of the antigen to the adjuvant/carrier was verified by SDS-PAGE, western blot, and ELISA. Immunization in C57BL/6J mice demonstrates that with Qβ - but not CPMV - there is an improved antibody response against the target antigen using the Qβ-NiNTA:His-OVA versus a simple admixture of antigen and adjuvant. Antibody isotyping also shows that formulation of the vaccines can alter T helper biases; while the Qβ-NiNTA:His-OVA particle produces a balanced Th1/Th2 bias the admixture was strongly Th2. In a mouse model of B16F10-OVA, we further demonstrate improved survival and slower tumor growth in the vaccine groups compared to controls. The NiNTA:His chemistry demonstrates potential for rapid development of future generation vaccines enabling plug-and-play capabilities with effectiveness boosted by co-delivery to the same cell.

100 项与 Immunodrug nicotine addiction vaccine(Cytos Biotechnology AG) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尼古丁依赖	临床2期	瑞士	Cytos Biotechnology AG	2003-12-01
尼古丁成瘾	临床2期	瑞士	Cytos Biotechnology AG	-
尼古丁成瘾	临床2期	德国	-	-
尼古丁成瘾	临床2期	美国	-	-
烟草依赖	临床2期	-	Duke University Medical Center	-
烟草依赖	临床2期	-	Wake Forest University	-